Adagio Therapeutics, Inc. Form 8-K Summary
Reporting date: February 23, 2022. The filing concerns a management and board transition. The filing entity is Adagio Therapeutics, Inc.; the request metadata identifies Invivyd, Inc., but the filing text does not explain the name difference.
Business Context and Reporting Period
- Adagio Therapeutics was a Delaware corporation with common stock traded on Nasdaq under the symbol ADGI.
- The filing was submitted under Items 5.02 and 8.01 and does not report quarterly or annual financial results.
Management and Board Changes
- Tillman U. Gerngross, Ph.D. resigned as Chief Executive Officer, President, and a member of the Board effective February 23, 2022.
- David Hering was appointed Interim Chief Executive Officer while continuing as Chief Operating Officer.
- The filing states that there was no arrangement or understanding regarding Mr. Hering’s selection, no family relationship with other directors or executive officers, and no disclosable related-party transaction under Item 404(a) of Regulation S-K.
- Tom Heyman resigned as a Class II director and was immediately reappointed as a Class III director solely to rebalance the Board’s three director classes. His Board service was otherwise deemed uninterrupted.
Financial Metrics and Liquidity
The filing does not provide revenue, profit or loss, cash flow, margins, debt, cash balances, liquidity measures, capital expenditures, or other financial results.
Outlook, Risks, and Unusual Items
- The principal disclosed event is the transition to interim CEO leadership.
- The filing provides no financial guidance, operating forecast, restructuring plan, severance terms, or detailed discussion of business risks or contingencies.
- A February 23, 2022 press release announcing Mr. Hering’s appointment was filed as Exhibit 99.1, but its substantive contents are not included in the provided filing text.
Key Facts for Investor Verification
- Verify the effective date and scope of Dr. Gerngross’s resignation.
- Review Exhibit 99.1 for management’s stated rationale, priorities, and additional commentary regarding the interim CEO appointment.
- Confirm Mr. Hering’s continuing role as Chief Operating Officer and the terms of any subsequent permanent CEO search or appointment.
- Confirm the Board classification change and its effect on director election terms.
- Review subsequent SEC filings for financial results, liquidity, financing activity, compensation arrangements, and further leadership changes.